CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...
Phase 2
Barcelona, Spain and 46 other locations
is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...
Phase 3
Barcelona, Spain and 17 other locations
people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)....
Phase 1
Barcelona, Spain and 13 other locations
Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood c...
Phase 3
Esplugues de Llobregat, Spain and 44 other locations
baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney...
Phase 2
Badalona, Spain and 67 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Barcelona, Spain and 328 other locations
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific t ...
Phase 2
Barcelona, Spain and 163 other locations
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medici...
Phase 3
Barcelona, Spain and 97 other locations
To evaluate the safety of tolvaptan in pediatric subjects with ARPKD
Phase 3
Barcelona, Spain and 22 other locations
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...
Phase 3
Barcelona, Spain and 339 other locations
Clinical trials
Research sites
Resources
Legal